The Continental landscape is witnessing a unique evolution in the perception of psychedelics. Historically stigmatized, these substances are increasingly be explored for their potential therapeutic applications. From Switzerland, where clinical trials are being conducted, to the France, where open conversations is increasing, Europe is at the foref